<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773407</url>
  </required_header>
  <id_info>
    <org_study_id>18NP</org_study_id>
    <nct_id>NCT02773407</nct_id>
  </id_info>
  <brief_title>Nepal Undifferentiated Febrile Illness Trial</brief_title>
  <acronym>NUFIT</acronym>
  <official_title>Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford University Clinical Research Unit, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford University Clinical Research Unit, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether azithromycin or cotrimoxazole is the best
      empirical treatment for undifferentiated febrile illness in Nepal
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fever is one of the most common presenting symptoms of patients presenting to health centers
      in Nepal. Many of the times, it is difficult to diagnose the cause of the fever by initial
      history, clinical examination and basic laboratory tests and the patents are treated as
      presumed enteric fever or fever without focus needing antimicrobials. In fact there are
      various causes of similarly presenting febrile illnesses including typhoid, paratyphoid,
      murine typhus, scrub typhus etc.

      Many of the traditionally used drugs including fluoroquinolones are now resistant against
      enteric fever in south asia. Oral azithromycin is now commonly used to treat undifferentiated
      febrile illness and remains effective against enteric fever. Many physicians now also use
      co-trimoxazole as it was very commonly used in the treatment of enteric fever in the past.
      Resistance to co-trimoxazole emerged two decades ago, but has subsequently largely
      disappeared and nearly all Salmonella Typhi and Paratyphi A strains from Nepal are now
      susceptible. Anecdotal reports claim that it seems to work very well against undifferentiated
      febrile illness in Nepal; it is largely stocked in government health facilities and is a
      popular and cheap treatment option.

      Both azithromycin and co-trimoxazole are available in Nepal and are extensively used in the
      treatment of undifferentiated febrile illness. Therefore it is important to know the better
      oral option to treat enteric fever and other febrile illnesses and also to have an
      alternative oral treatment in case resistance to azithromycin emerges.

      The investigators purpose to conduct a head to head, parallel group, 1:1, double blinded
      randomized controlled trial to compare azithromycin and co-trimoxazole for the treatment of
      undifferentiated febrile illness and determine the best empirical treatment for
      undifferentiated febrile illness in Nepal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fever clearance time</measure>
    <time_frame>at least 2 days</time_frame>
    <description>time from the first dose of a study drug until a temperature ≤37.5°C for at least 2 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever failure</measure>
    <time_frame>over 7 days post treatment initiation</time_frame>
    <description>defined by fever clearance time (FCT) &gt;7 days post treatment initiation;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for rescue treatment as judged by the Research Medical Officer (RMO) and Attending Physician (AP)</measure>
    <time_frame>within 63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood culture positivity for S. Typhi or an S. Paratyphi</measure>
    <time_frame>on day 7 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culture-confirmed or syndromic enteric fever relapse</measure>
    <time_frame>within 28 days of initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development of any complication</measure>
    <time_frame>within 28 days of initiation of treatment</time_frame>
    <description>any complication: e.g. clinically significant bleeding, fall in the Glasgow Coma Score, perforation of the gastrointestinal tract and hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-treatment failure</measure>
    <time_frame>within 63 days</time_frame>
    <description>the time from the first dose of treatment until the date of the earliest failure event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>within 63 days</time_frame>
    <description>grade 3/4 adverse events, serious adverse events, adverse events of any grade leading to modification of study drug dose or interruption/early discontinuation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Undifferentiated Febrile Illness</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-trimoxazole</intervention_name>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fever of ≥ 38.0°C and for ≥4 days without a focus of infection

          -  ≥ 2 years and &lt;65 years of age

          -  Able to take tablets orally

          -  Patient residing in Kathmandu Valley

          -  Able to come for follow up

          -  Can be reached by telephone/mobile phone 24 hours a day.

          -  Written informed consent to participate in the study including assent for minors in
             addition to parental consent.

        Exclusion Criteria:

          -  Fever &gt;14 days

          -  Pregnancy

          -  Obtundation

          -  Shock

          -  Visible jaundice

          -  Presence of signs of gastrointestinal bleeding

          -  History of hypersensitivity to either of the trial drugs

          -  Patient requiring intravenous antibiotic or hospital admission for any reason.

          -  Contraindication of drug for any reason (e.g. drug interactions).

          -  Any patient fulfilling inclusion criteria but already on antimicrobials and responding
             clinically to the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Buddha Basnyat, MBBS,MSc,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Buddha Basnyat, MBBS,MSc,MD</last_name>
    <phone>+977-9851034187</phone>
    <email>buddhabasnyat@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunil Pokharel, Dr</last_name>
    <phone>+9779841429460</phone>
    <email>sunildrp@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nepal Civil Service Hospital</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damodar Gajurel, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Patan Hospital</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buddha Basnyat, MBBS,MSc,MD</last_name>
      <phone>+ 977-9851034187</phone>
      <email>buddhabasnyat@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <reference>
    <citation>Crump JA, Kirk MD. Estimating the Burden of Febrile Illnesses. PLoS Negl Trop Dis. 2015 Dec 3;9(12):e0004040. doi: 10.1371/journal.pntd.0004040. eCollection 2015 Dec. Review.</citation>
    <PMID>26633014</PMID>
  </reference>
  <reference>
    <citation>Zimmerman MD, Murdoch DR, Rozmajzl PJ, Basnyat B, Woods CW, Richards AL, Belbase RH, Hammer DA, Anderson TP, Reller LB. Murine typhus and febrile illness, Nepal. Emerg Infect Dis. 2008 Oct;14(10):1656-9. doi: 10.3201/eid1410.080236.</citation>
    <PMID>18826840</PMID>
  </reference>
  <reference>
    <citation>Thompson CN, Blacksell SD, Paris DH, Arjyal A, Karkey A, Dongol S, Giri A, Dolecek C, Day N, Baker S, Thwaites G, Farrar J, Basnyat B. Undifferentiated febrile illness in Kathmandu, Nepal. Am J Trop Med Hyg. 2015 Apr;92(4):875-8. doi: 10.4269/ajtmh.14-0709. Epub 2015 Feb 9.</citation>
    <PMID>25667056</PMID>
  </reference>
  <reference>
    <citation>Koirala S, Basnyat B, Arjyal A, Shilpakar O, Shrestha K, Shrestha R, Shrestha UM, Agrawal K, Koirala KD, Thapa SD, Karkey A, Dongol S, Giri A, Shakya M, Pathak KR, Campbell J, Baker S, Farrar J, Wolbers M, Dolecek C. Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial. PLoS Negl Trop Dis. 2013 Oct 31;7(10):e2523. doi: 10.1371/journal.pntd.0002523. eCollection 2013.</citation>
    <PMID>24282626</PMID>
  </reference>
  <reference>
    <citation>Arjyal A, Basnyat B, Nhan HT, Koirala S, Giri A, Joshi N, Shakya M, Pathak KR, Mahat SP, Prajapati SP, Adhikari N, Thapa R, Merson L, Gajurel D, Lamsal K, Lamsal D, Yadav BK, Shah G, Shrestha P, Dongol S, Karkey A, Thompson CN, Thieu NTV, Thanh DP, Baker S, Thwaites GE, Wolbers M, Dolecek C. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. Lancet Infect Dis. 2016 May;16(5):535-545. doi: 10.1016/S1473-3099(15)00530-7. Epub 2016 Jan 20.</citation>
    <PMID>26809813</PMID>
  </reference>
  <reference>
    <citation>Dolecek C, Tran TP, Nguyen NR, Le TP, Ha V, Phung QT, Doan CD, Nguyen TB, Duong TL, Luong BH, Nguyen TB, Nguyen TA, Pham ND, Mai NL, Phan VB, Vo AH, Nguyen VM, Tran TT, Tran TC, Schultsz C, Dunstan SJ, Stepniewska K, Campbell JI, To SD, Basnyat B, Nguyen VV, Nguyen VS, Nguyen TC, Tran TH, Farrar J. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One. 2008 May 21;3(5):e2188. doi: 10.1371/journal.pone.0002188.</citation>
    <PMID>18493312</PMID>
  </reference>
  <reference>
    <citation>Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, Tham NT, Wain J, Hien TT, Farrar JJ. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother. 2007 Mar;51(3):819-25. Epub 2006 Dec 4.</citation>
    <PMID>17145784</PMID>
  </reference>
  <reference>
    <citation>Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, Wain J, White NJ, Farrar JJ. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000 Jul;44(7):1855-9.</citation>
    <PMID>10858343</PMID>
  </reference>
  <reference>
    <citation>Chand HJ, Rijal KR, Neupane B, Sharma VK, Jha B. Re-emergence of susceptibility to conventional first line drugs in Salmonella isolates from enteric fever patients in Nepal. J Infect Dev Ctries. 2014 Nov 13;8(11):1483-7. doi: 10.3855/jidc.4228.</citation>
    <PMID>25390062</PMID>
  </reference>
  <reference>
    <citation>Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, Yadav B, Stepniewska K, Campbell JI, Dolecek C, Farrar JJ, Basnyat B. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One. 2007 Jun 27;2(6):e542.</citation>
    <PMID>17593957</PMID>
  </reference>
  <reference>
    <citation>Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. Lancet Infect Dis. 2011 Jun;11(6):445-54. doi: 10.1016/S1473-3099(11)70089-5. Epub 2011 Apr 29.</citation>
    <PMID>21531174</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>April 8, 2018</last_update_submitted>
  <last_update_submitted_qc>April 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Undifferentiated febrile illness</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Cotrimoxazole</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Enteric fever</keyword>
  <keyword>Fever clearance time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised individual participant data will be made available to researcher and public as a supporting material via open access journal and/or upon request by qualified research groups</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

